{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,7]],"date-time":"2026-06-07T21:19:09Z","timestamp":1780867149105,"version":"3.54.1"},"reference-count":25,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2025,4,26]],"date-time":"2025-04-26T00:00:00Z","timestamp":1745625600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:p>\n                    Developing new therapeutic regimens for relapsed\/refractory (R\/R) B non\u2010Hodgkin lymphoma (NHL) patients remains a significant unmet clinical need. Our objective was to evaluate atezolizumab (ATE), obinutuzumab (OBI) and venetoclax (VEN) combination in patients with R\/R NHL who had received at least one prior anti\u2010CD20\u2010containing immunochemotherapy regimen. We report here the final analysis of the phase II LYSA\u2010promoted multicentre trial (NCT03276468) of this combination in follicular lymphoma (FL,\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200958), diffuse large B\u2010cell lymphoma (DLBCL,\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200958) and marginal zone lymphoma (MZL,\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200920). The primary end\u2010point for FL and DLBCL was not met: ATE, OBI, and VEN resulted in an overall response rate (ORR) at the end of induction (EOI) of 53.6% for FL (cohort 1) and 23.6% for DLBCL (cohort 2) when a minimum of 70% and 48% was expected respectively. The median progression\u2010free survival was 11.0 and 2.7\u2009months in cohorts 1 and 2 respectively. In cohort 3 (MZL), the ORR at the EOI was evaluated at 66.7%. The most frequent adverse events (AEs) were cytopenias. We also observed 7.4% of autoimmune AE imputable to the combination. In this phase II study, ATE, OBI and VEN demonstrated moderate efficacy and a manageable toxicity profile when used as induction and maintenance therapy.\n                  <\/jats:p>","DOI":"10.1111\/bjh.20109","type":"journal-article","created":{"date-parts":[[2025,4,26]],"date-time":"2025-04-26T03:19:33Z","timestamp":1745637573000},"page":"110-122","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Atezolizumab, obinutuzumab and venetoclax for the treatment of patients with relapsed\/refractory B non\u2010Hodgkin lymphoma: Final analysis of a phase II trial from the\n                    <scp>LYSA<\/scp>\n                    group"],"prefix":"10.1111","volume":"207","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4910-476X","authenticated-orcid":false,"given":"Charles","family":"Herbaux","sequence":"first","affiliation":[{"name":"Service d'H\u00e9matologie Clinique UMR\u2010CNRS 5535, CHU Montpellier, Universit\u00e9 de Montpellier  Montpellier Cedex France"},{"name":"Institute of Human Genetics, UMR CNRS\u2010UM, 9002  Montpellier France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Bachy","sequence":"additional","affiliation":[{"name":"CHU Lyon\u2010Sud  Pierre\u2010Benite France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reda","family":"Bouabdallah","sequence":"additional","affiliation":[{"name":"Institut Paoli Calmettes  Marseille France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8755-5591","authenticated-orcid":false,"given":"St\u00e9phanie","family":"Guidez","sequence":"additional","affiliation":[{"name":"CHU de Poitiers \u2013 Hopital de Louisiana Miletrie  Poitiers France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Casasnovas","sequence":"additional","affiliation":[{"name":"CHU Dijon Bourgogne  Dijon France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Feugier","sequence":"additional","affiliation":[{"name":"CHU Brabois  Vandoeuvre\u2010les\u2010Nancy France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gandhi","family":"Damaj","sequence":"additional","affiliation":[{"name":"Institut d'H\u00e9matologie CHU de Caen, Universit\u00e9 de Normadie, UFR de M\u00e9decine  Caen France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herv\u00e9","family":"Tilly","sequence":"additional","affiliation":[{"name":"Centre Henri Becquerel  Rouen France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4102-7261","authenticated-orcid":false,"given":"Lo\u00efc","family":"Ysebaert","sequence":"additional","affiliation":[{"name":"IUCT Oncopole  Toulouse France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Le Gouill","sequence":"additional","affiliation":[{"name":"Service d'h\u00e9matologie Institut Curie  Saint Cloud France"},{"name":"Universit\u00e9 de Versailles Saint\u2010Quentin (UVSQ)  Saint\u2010Quentin\u2010en\u2010Yvelines France"},{"name":"Laboratoire d'Imagerie Translationnelle en Oncologie (LITO) U1288 Inserm\/Institut Curie Centre de Recherche, France  Paris Cedex France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadine","family":"Morineau","sequence":"additional","affiliation":[{"name":"CHD de Vend\u00e9e  La Roche\u2010sur\u2010Yon France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Gyan","sequence":"additional","affiliation":[{"name":"Service d'h\u00e9matologie et th\u00e9rapie cellulaire CIC INSERM U1415, Centre Hospitalier Universitaire de Tours, Universit\u00e9 de Tours  Tours France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R\u00e9my","family":"Gressin","sequence":"additional","affiliation":[{"name":"Hematology Department Univ. Grenoble Alpes, Grenoble Alpes University Hospital  Grenoble France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roch","family":"Houot","sequence":"additional","affiliation":[{"name":"Department of Hematology CHU Rennes, University of Rennes  Rennes France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgane","family":"Cheminant","sequence":"additional","affiliation":[{"name":"Clinical Hematology Necker\u2010Enfants Malades University Hospital, AP\u2010HP  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franck","family":"Morschhauser","sequence":"additional","affiliation":[{"name":"CHRU de Lille \u2013 Hopital Claude Huriez  Lille France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Thieblemont","sequence":"additional","affiliation":[{"name":"Hemato\u2010Oncologie Assistance Publique \u2013 H\u00f4pitaux de Paris, H\u00f4pital Saint Louis  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corinne","family":"Haioun","sequence":"additional","affiliation":[{"name":"Department of Lympho\u00efd Hematology H\u00f4pital Henri Mondor, AP\u2010HP  Cr\u00e9teil France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuelle","family":"Nicolas\u2010Virelizier","sequence":"additional","affiliation":[{"name":"Centre L\u00e9on Berard  Lyon France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc\u2010Matthieu","family":"Fornecker","sequence":"additional","affiliation":[{"name":"Institut Delaware Cancerologie Strasbourg Europe  Strasbourg France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Daguindau","sequence":"additional","affiliation":[{"name":"H\u00e9matologie clinique, CH Annecy, Genevois  Epagny Metz\u2010Tessy France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Cartron","sequence":"additional","affiliation":[{"name":"Service d'H\u00e9matologie Clinique UMR\u2010CNRS 5535, CHU Montpellier, Universit\u00e9 de Montpellier  Montpellier Cedex France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,4,26]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2023.0057"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2020.1727445"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2015.213"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2013.07.012"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.59.2139"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-05-504043"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.70.4320"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2019.11.003"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.aav7062"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2016.150656"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1016569108"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-19-0759"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(24)00396-6"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.95"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2020.1811271"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-05861-0"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1177\/2040620715622613"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021006520"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2021.12.010"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2023.101636"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00539-8"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.594841"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022009066"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-05-718528"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023009911"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.20109","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T10:19:55Z","timestamp":1765534795000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.20109"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,26]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["10.1111\/bjh.20109"],"URL":"https:\/\/doi.org\/10.1111\/bjh.20109","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,26]]},"assertion":[{"value":"2024-12-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-04-11","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-04-26","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}